Castano-Bonilla, T; Barragan, E; Sargas, C; Sanz, A; Algarra, L; Herrera-Puente, P; Garcia-Boyero, R; Barrios, M; Martinez-Cuadron, D; Rodriguez-Veiga, R; Boluda, B; Gil, C; Serrano-Lopez, J; Martinez-Lopez, J; Sayas-Lloris, MJ; Olave, MT; Riaza-Grau, R; Bernal-Del Castillo, T; Larrayoz, MJ; Amigo, R; Jimenez-Velasco, A; Sanchez, J; Ayala, R; Blas, C; Lainez, D; Serrano-Lopez, J; Sanz, MA; Alonso-Dominguez, JM; Montesinos, P – 2022
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
by prodriguez | Jan 1, 2022 | Publicaciones - B-03 | 0 comments